Home Oxygen Consent Form (HOCF)(85 KB)
Date added: 9th Jul 2026
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| TIRZEPATIDE (Mounjaro®) (UPDATED) | Green | Management of overweight and obesity |
For managing overweight and obesity in adults in line with NICE TA1026. March 2026: Green for eligible cohort only as per LLR weight management guide |
| 5- FLUROURACIL CREAM (Efudix®, Tolak®) (NEW) | Green | for actinic keratosis |
Usually formulary choice is 5% cream (Efudix ®) but whilst supply shortage 4% cream is available as alternative (Tolak ®)
|
| CICLOSPORIN 0.09% EYE DROPS (Cequa®) (NEW) | Yellow | Treatment of moderate-to-severe Dry Eye Disease |
An alternative preparation to Ikervis® Specialist ophthalmologist initiation for use in line with NICE TA 369 only for treating severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes. Prescribe by brand. |
| CICLOSPORIN 0.1% EYE DROPS (Vevizye®) (NEW) | Yellow | Treatment of moderate-to-severe Dry Eye Disease |
Alternative if Cequa® not tolerated Specialist ophthalmologist initiation for use in line with NICE TA 369 only for treating severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes. Prescribe by brand. Cetalkonium chloride free formulation. |
| CICLOSPORIN EYE DROPS (Verkazia®) | Yellow | Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents | |
| CICLOSPORIN OPTHALMIC EMULSION (Ikervis®) | Yellow | Dry eye disease |
Specialist ophthalmologist initiation for use in line with NICE TA 369 only for treating severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes. Prescribe by brand. |
| DAPAGLIFLOZIN (UPDATED) | Green | Type 2 diabetes |
Conditional on prescriber being competent to select appropriate patients. For use in monotherapy to treat T2DM in line with NICE TA390 and for use in line with NICE TA288 as part of combination therapy to treat T2DM |
| DAPAGLIFLOZIN (NEW) | Green | Chronic Heart failure with reduced ejection fraction or mildly reduced ejection fraction |
For prescribers who feel competent, in line with the updated LLR HF guide; others should refer back to specialist services In line with NICE TA902 and NICE TA679 |
| DAPAGLIFLOZIN (UPDATED) | Yellow | Chronic Heart failure with preserved ejection fraction |
In line with NICE TA902 |
| DAPAGLIFLOZIN | Do not prescribe | Type 1 diabetes |
Dapagliflozin is no longer licensed for use in T1DM due to commercial reasons. The NICE TA for this indication has been withdrawn. Patients already taking dapagliflozin for this indication should continue. |
| Dexcom ONE+® (UPDATED) | Yellow | Diabetes Continuous glucose monitoring (CGM) |
Dexcom ONE+ ® is approved for use in Leicester, Leicestershire and Rutland for diabetes glucose monitoring where a patient meets the criteria detailed in the LLR APC position statement.
|
| GOSERELIN | Yellow | Endometriosis, uterine fibroids | |
| GOSERELIN 3.6mg (Zoladex®) (UPDATED) | Yellow | Breast cancer |
Zoladex 3.6mg implant is the only licensed product for breast cancer
|
| INFLIXIMAB | Red | All indications |
As indicated on the LLR Medicines Formulary |
| LEUPRORELIN | Yellow | Endometriosis, uterine fibroids | |
| LEUPRORELIN (PROSTAP 3 DCS ®) | Yellow | Breast cancer |
3 monthly preparation |
| LOTEPREDNOL ETABONATE eye drops (Lotemax®) (UPDATED) | Yellow | Post-operative inflammation following ocular surgery |
Ophthalmic inflammatory conditions needing topical steroid where standard drops have caused, or may cause, raised intraocular pressure (IOP). |
| MEPOLIZUMAB (NEW) | Red | For maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils |
In line with NICE TA1166 Funding from 15th September 2026 |
| SEMAGLUTIDE (Wegovy®) (NEW) | Yellow | Reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity |
In line with NICE TA1152 Funding from 5th August 2026 |
| TIRZEPATIDE (Mounjaro®) (NEW) | Red | For use in dialysis or pre-dialysis patients with BMI >37 who otherwise would be suitable for renal transplant | |
| TRIPTORELIN | Yellow | Endometriosis, uterine fibroids | |
| VEDOLIZUMAB (NEW) | Red | For immunotherapy related colitis |
As per ESMO guidelines |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLR APC Meeting Minutes June 2026(484 KB) - LMSG/LLR APC minutes
Date added: 8th Jul 2026
TAS Minutes 26th May 2026(334 KB) - TAS
Date added: 24th Jun 2026
LLRAPC Newsletter – June 2026(529 KB) - LMSG/LLR APC newsletters
Date added: 19th Jun 2026
ADHD Paediatric SCA Request form(56 KB)
Date added: 11th Jun 2026
Adult ADHD Shared Care Request Form National Format(407 KB) - Shared care agreement
Date added: 29th Dec 2022
Home Oxygen Pathway for Cluster Headache(259 KB) - Guidelines
Date added: 10th Nov 2020
Process for requesting changes to the wound formulary(272 KB) - Guidelines
Date added: 6th Dec 2019
Heart Failure – Management in Primary Care(470 KB) - Guidelines
Date added: 8th Apr 2019
Oxygen Ordering and Referral Pathway Guide(267 KB) - Guidelines
Date added: 9th May 2018
Home Oxygen Referral Form(245 KB) - Guidelines
Date added: 2nd May 2018
EOL Pathway For Oxygen(336 KB) - Guidelines
Date added: 2nd May 2018
Oxygen Prescribing Guidance(296 KB) - Guidelines
Date added: 20th Mar 2018
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more